Hematopoietic Stem Cell Transplantation - Pipeline Review, H1 2015

Description:

Hematopoietic Stem Cell Transplantation - Pipeline Review, H1 2015

Summary

This, ‘Hematopoietic Stem Cell Transplantation - Pipeline Review, H1 2015’, provides an overview of the Hematopoietic Stem Cell Transplantation's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Hematopoietic Stem Cell Transplantation, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hematopoietic Stem Cell Transplantation and special features on late-stage and discontinued projects.

This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from This proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by This team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Hematopoietic Stem Cell Transplantation
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Hematopoietic Stem Cell Transplantation and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Hematopoietic Stem Cell Transplantation products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Hematopoietic Stem Cell Transplantation pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for
Hematopoietic Stem Cell Transplantation
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Hematopoietic Stem Cell Transplantation pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Contents:

List of Tables
List of Figures
Introduction
REPORT COVERAGE
Hematopoietic Stem Cell Transplantation Overview
Therapeutics Development
Pipeline Products for Hematopoietic Stem Cell Transplantation - Overview
Pipeline Products for Hematopoietic Stem Cell Transplantation - Comparative Analysis
Hematopoietic Stem Cell Transplantation - Therapeutics under Development by Companies
Hematopoietic Stem Cell Transplantation - Pipeline Products Glance
Clinical Stage Products
Early Stage Products
Hematopoietic Stem Cell Transplantation - Products under Development by Companies
Hematopoietic Stem Cell Transplantation - Companies Involved in Therapeutics Development
Actinium Pharmaceuticals, Inc.
Athersys, Inc.
BioLineRx, Ltd.
Cellidex Therapeutics, Inc.
Cellerant Therapeutics, Inc.
Kiadis Pharma B.V.
Novartis AG
P2D Bioscience
Pharmalink AB
Polyphor Ltd.
Recoly N.V.
TaiGen Biotechnology Co., Ltd.
Targazine, Inc.
TikoMed AB
Hematopoietic Stem Cell Transplantation - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
Actimab-B - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ATIR - Drug Profile
Product Description
Mechanism of Action
R&D Progress
BL-8040 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
burixafor - Drug Profile
Product Description
Mechanism of Action
R&D Progress
busulfan liposomal IR - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Casin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
CDX-301 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
CordSafe - Drug Profile
Product Description
Mechanism of Action
R&D Progress
HSC-835 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Iomab-B - Drug Profile
Product Description
Mechanism of Action
R&D Progress
MultiStem - Drug Profile
Product Description
Mechanism of Action
R&D Progress
NecLipG-CSF - Drug Profile
Product Description
Mechanism of Action
R&D Progress
POL-5551 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
POL-6326 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
romyelocel-L - Drug Profile
Product Description
Mechanism of Action
R&D Progress
TM-400 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
TXA-127 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
TZ-101 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Hematopoietic Stem Cell Transplantation - Recent Pipeline Updates
Hematopoietic Stem Cell Transplantation - Dormant Projects
Hematopoietic Stem Cell Transplantation - Discontinued Products
Hematopoietic Stem Cell Transplantation - Product Development Milestones
Featured News & Press Releases
Apr 23, 2015: Targazyme Announces FDA Concurrence On Targazyme’s Special Protocol Assessment For A Planned Phase 3 Registration Trial For The Treatment Of Patients With Hematologic Malignancies
Mar 18, 2015: TaiGen Biotechnology Announces Burixafor Collaboration with Cellex and the University Hospital Carl Gustav Carus Dresden in Germany
Mar 17, 2015: Targazyme and M.D. Anderson Cancer Center Receive FDA IND Clearance for Phase I/II Study of TZ101-Treated Regulatory T Cells to Prevent Graft vs Host Disease in Patients Eligible for Hematologic Stem Cell Transplantation

Feb 10, 2015: Targazyme Receives Orphan Drug Designation to TZ101 for Use With Regulatory T Cells to Prevent & Reduce the Severity of Graft Versus Host Disease in Patients Eligible for Hematologic Stem Cell Transplantation

Sep 25, 2014: Celldex Therapeutics Initiates Pilot Study of CDX-301 in Allogeneic Hematopoietic Stem Cell Transplantation

Sep 03, 2014: BioLineRx Doses First Patient for BL-8040's Second Indication as Novel Stem Cell Mobilization Treatment

Jun 08, 2014: ScinoPharm to Provide Active Pharmaceutical Ingredient to FTaiGen for Novel Stem Cell Drug

Jan 29, 2014: Actinium Engages Goodwin Biotechnology to Supply Iomab-B for Its Phase 3 Clinical Study

Dec 19, 2013: Actinium Completes Technology Transfer for Manufacturing of Its Lead Drug Candidate Iomab-B

Dec 18, 2013: Targazyme Reports Interim Phase I/Ia Trial Results for TZ101

Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development for Hematopoietic Stem Cell Transplantation, H1 2015
Number of Products under Development for Hematopoietic Stem Cell Transplantation - Comparative Analysis, H1 2015
Number of Products under Development by Companies, H1 2015
Comparative Analysis by Clinical Stage Development, H1 2015
Comparative Analysis by Early Stage Development, H1 2015
Products under Development by Companies, H1 2015
Hematopoietic Stem Cell Transplantation - Pipeline by Actinium Pharmaceuticals, Inc., H1 2015
Hematopoietic Stem Cell Transplantation - Pipeline by Athersys, Inc., H1 2015
Hematopoietic Stem Cell Transplantation - Pipeline by BioLineRx, Ltd., H1 2015
Hematopoietic Stem Cell Transplantation - Pipeline by Celldex Therapeutics, Inc., H1 2015
Hematopoietic Stem Cell Transplantation - Pipeline by Cellerant Therapeutics, Inc., H1 2015
Hematopoietic Stem Cell Transplantation - Pipeline by Kiadis Pharma B.V., H1 2015
Hematopoietic Stem Cell Transplantation - Pipeline by Novartis AG, H1 2015
Hematopoietic Stem Cell Transplantation - Pipeline by P2D Bioscience, H1 2015
Hematopoietic Stem Cell Transplantation - Pipeline by Pharmalink AB, H1 2015
Hematopoietic Stem Cell Transplantation - Pipeline by Polyphor Ltd., H1 2015
Hematopoietic Stem Cell Transplantation - Pipeline by Recoly N.V., H1 2015
Hematopoietic Stem Cell Transplantation - Pipeline by TaiGen Biotechnology Co., Ltd., H1 2015
Hematopoietic Stem Cell Transplantation - Pipeline by Targazyme, Inc., H1 2015
Hematopoietic Stem Cell Transplantation - Pipeline by TikoMed AB, H1 2015
Assessment by Monotherapy Products, H1 2015
Number of Products by Stage and Target, H1 2015
Number of Products by Stage and Mechanism of Action, H1 2015
Number of Products by Stage and Route of Administration, H1 2015
Number of Products by Stage and Molecule Type, H1 2015
Hematopoietic Stem Cell Transplantation Therapeutics - Recent Pipeline Updates, H1 2015
Hematopoietic Stem Cell Transplantation - Dormant Projects, H1 2015
Hematopoietic Stem Cell Transplantation - Discontinued Products, H1 2015

List of Figures
Number of Products under Development for Hematopoietic Stem Cell Transplantation, H1 2015
Number of Products under Development for Hematopoietic Stem Cell Transplantation - Comparative Analysis, H1 2015
Number of Products under Development by Companies, H1 2015
Comparative Analysis by Clinical Stage Development, H1 2015
Comparative Analysis by Early Stage Products, H1 2015
Assessment by Monotherapy Products, H1 2015
Number of Products by Top 10 Targets, H1 2015
Number of Products by Stage and Top 10 Targets, H1 2015
Number of Products by Top 10 Mechanism of Actions, H1 2015
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015
Number of Products by Top 10 Routes of Administration, H1 2015
Number of Products by Stage and Top 10 Routes of Administration, H1 2015
Number of Products by Top 10 Molecule Types, H1 2015
Number of Products by Stage and Top 10 Molecule Types, H1 2015

Ordering:

Order Online - http://www.researchandmarkets.com/reports/3293085/

Order by Fax - using the form below

Order by Post - print the order form below and send to

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.
Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to 646-607-1907 (from USA) or +353-1-481-1716 (from Rest of World). If you have any questions please visit

http://www.researchandmarkets.com/contact/

Order Information
Please verify that the product information is correct and select the format(s) you require.

- Product Name: Hematopoietic Stem Cell Transplantation - Pipeline Review, H1 2015
- Web Address: http://www.researchandmarkets.com/reports/3293085/
- Office Code: SC

Product Formats
Please select the product formats and quantity you require:

<table>
<thead>
<tr>
<th>Format</th>
<th>Price</th>
</tr>
</thead>
<tbody>
<tr>
<td>Electronic (PDF) - Single User</td>
<td>USD 2000</td>
</tr>
<tr>
<td>Electronic (PDF) - Site License</td>
<td>USD 4000</td>
</tr>
<tr>
<td>Electronic (PDF) - Enterprisewide</td>
<td>USD 6000</td>
</tr>
</tbody>
</table>

* The price quoted above is only valid for 30 days. Please submit your order within that time frame to avail of this price as all prices are subject to change.

Contact Information
Please enter all the information below in BLOCK CAPITALS

Title: [ ] Mr  [ ] Mrs  [ ] Dr  [ ] Miss  [ ] Ms  [ ] Prof
First Name: ___________________________ Last Name: ___________________________
Email Address: * ___________________________
Job Title: ___________________________
Organisation: ___________________________
Address: ___________________________
City: ___________________________
Postal / Zip Code: ___________________________
Country: ___________________________
Phone Number: ___________________________
Fax Number: ___________________________

* Please refrain from using free email accounts when ordering (e.g. Yahoo, Hotmail, AOL)
Payment Information

Please indicate the payment method you would like to use by selecting the appropriate box.

☐ Pay by credit card: You will receive an email with a link to a secure webpage to enter your credit card details.

☐ Pay by check: Please post the check, accompanied by this form, to:
Research and Markets,
Guinness Center,
Taylors Lane,
Dublin 8,
Ireland.

☐ Pay by wire transfer:

Please transfer funds to:
Account number 833 130 83
Sort code 98-53-30
Swift code ULSBIE2D
IBAN number IE78ULSB98533083313083
Bank Address Ulster Bank,
27-35 Main Street,
Blackrock,
Co. Dublin,
Ireland.

If you have a Marketing Code please enter it below:

Marketing Code: ____________________________

Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp

Please fax this form to:
(646) 607-1907 or (646) 964-6609 - From USA
+353-1-481-1716 or +353-1-653-1571 - From Rest of World